Elucid Announces CCTA Reimbursement to be Doubled with CMS Rule

Nov 4, 2024 | In the News

Decision makes crucial cardiovascular imaging and CT-based technologies more economically viable to hospital outpatient and ambulatory care providers BOSTON – November 4, 2024 – Elucid Bioimaging, Inc. has announced a final rule from US Centers for Medicare &...

Elucid Announces Fifth Medicare Administrative Contractor to Cover AI Coronary Plaque Analysis

Oct 25, 2024 | Press Releases

Noridian latest MAC to make Elucid PlaqueIQTM image analysis software available for eligible patients BOSTON – October 25, 2024 – Elucid has announced that Noridian will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared...

Elucid Announces Favorable Medicare Coverage of AI Coronary Plaque Analysis

Oct 15, 2024 | Press Releases

New policy to make company’s PlaqueIQTM image analysis software available to eligible patients with suspected coronary artery disease BOSTON – October 15, 2024 – Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend...

Elucid Appoints Windi Hary to Lead Regulatory Affairs and Quality Management

Sep 6, 2023 | Press Releases

BOSTON, Sept. 6, 2023 – Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, has hired Windi Hary as senior vice president (SVP) of regulatory affairs and quality...

Elucid’s Next-Generation Plaque Analysis and FFR_CT Technology to be Featured on 2022 AHA Scientific Sessions Program

Nov 4, 2022 | Press Releases

BOSTON – November 4, 2022 – Elucid, Inc., a medical technology company providing physicians AI-powered imaging analysis software to characterize cardiovascular disease, has announced that the company’s technology will be featured on the program at the 2022 American...